Special Interest Group

SIG meetings connect members with common goals and interests, providing a platform to network and participate in knowledge and resource sharing amongst peers. These meetings also serve as resources for INASL to develop and promote specialty-specific programs and services. The participation in these meetings is voluntary and self-selected by INASL members based on their interest in research and clinical medicine. These meetings will have focused discussions on burning issues in Hepatology by experts in these areas with active participation by the delegates. This year we have decided to have SIG meetings on hepatitis C, hepatitis B, alcoholic liver disease, non-alcoholic fatty liver disease, drug induced liver disease, acute-on-chronic liver failure, ascites and hepatic encephalopathy.


SIG Meeting Schedule -INASL 2016

DATE
HALL
TOPIC
TIME
5th Aug 2016
Hall 1
HCV
08:00-09:00 Hrs
Hall 2
HBV
6th Aug 2016
Hall 1
NAFLD
Hall 2
HE /ALF
Hall 3
DILI
7th Aug 2016
Hall 1
ACLF
Hall 2
Ascites



Day 1 Hall 1(POSTGRADUATE COURSE)

 

Duration (min)

Speaker

Chairperson(s)

Time

5th August 2016 [Hall 1]        

Special Interest Group (SIG)meeting on HCV

  • Hepatitis C Control in Punjab
  • Pitfalls and potholes: how to avoid them
  • INASL HCV Guidelines: what’s new?
  • INASL HCV Online Registry: Ready to go
  • Discussion and Suggestions

60 min

12 min
10 min
12 min
12 min
14 min


R K Dhiman
Ajit Sood
Vivek A Saraswat
Ajay Duseja


Subrat Acharya
Vivek A Saraswat

08.00-09.00

5th August 2016 [Hall 2]        

Special Interest Group (SIG) meeting on HBV (Hall 2)

  1.   The burden of HBV infection in India and global trends.
  2.   The stratgies to extend the antiviral therapies for masses in India.
  3.   Limitations of antiviral drugs in India.
  4.   The central registry for data collection in India of HBV related liver diseases.

60 min



Padaki N Rao
Vinod K dixit
Anil Arora
Ramesh R Rai



Vinod K Dixit
Anil Arora

08.00-09.00

6th August 2016 [Hall 1]        

SIG meeting on NAFLD

  • Mechanisms of NASH progression
  • HCC in non-cirrhotic NASH – Fact or Fiction
  • NAFLD SIG – What next?
  • Discussion

60 min

15 min
15 min
10 min
20 min



ArunSanyal
Ajay Duseja
SP Singh



SP Singh
Ajay Duseja

08.00-09.00

6th August 2016 [Hall 2]        

SIG Meeting on HE
Management of HE in outpatients

  • Burden Minimal/Covert HE – Does it matter in daily life?
  • Approach to manage a patient with covert HE
  • Primary/secondary prevention
  • ALF Registry
  • Discussion

60 min

10 min
15 min
10 min
10 min

15 min

 

Vivek A Saraswat
Jasmohan Bajaj
Barjesh Sharma
Sunil Taneja

 

Vivek A Saraswat
RK Dhiman

08.00-09.00

6th August 2016 [Hall 3]        

SIG meeting on Ascites

  • What do we plan?
  • Management of refractory ascites
  • Beta Blockers in Cirrhotic Ascites:Recent advances
  • Recent advances in spontaneous bacterial peritonitis
  • Discussion

60 min


V. Singh
Rakhi Maiwal
Paolo Angeli

………………


V Singh
RakhiMaiwal

08.00-09.00

         
7th August 2016 [Hall 1]        

SIG meeting on ACLF

    1. ICARE: Work till date and presentation of ACLF data; Online registry for data collection
    2. Current projects (multicentre): SCLAFI (slow, continuous, low dose albumin-furosemide infusion) vs LVP for large Ascites
    3. Discussion
    4. Concluding remark

60 min


Shalimar

Gaurav Pandey

Ajay Duseja
Subrat Acharya


S.K Acharya
Vivek A Saraswat

08.00-09.00

         
7th August 2016 [Hall 1]        

SIG meeting on DILI

  • What have we achieved thus far? The way forward!
  • Adaptation or DILI: That is the question
  • Newer concepts in DILI: 
    1. DILI caused by biological, checkpoint inhibitors used to treat cancers, monoclonal antibody-induced DILI
    2. HILI (herbal induced liver injury), SILI (statin-induced liver injury), CASH (chemotherapy associated steatohepatitis)
  • Discussion

60 min

10 min
15 min

10 min

10 min

15 min



HarshadDevarbhavi
Mallikarjun

HarshadDevarbhavi

Varghese Thomas



Harshad Devarbhavi

RK Dhiman

08.00-09.00

         

Day 2 Hall 1

 

Duration (min)

Speaker

Chairperson(s)

Time

SIG meeting on NAFLD

  1.   Mechanisms of NASH progression
  2.   HCC in non-cirrhotic NASH – Fact or Fiction
  3.   NAFLD SIG – What next?
  4.   Discussion15 min

60 min
15 min
15 min
10 min
20 min

 

Arun Sanyal
Ajay Duseja
SP Singh

SP Singh
Ajay Duseja

08.00-09.00

Day 2 Hall 2

 

Duration (min)

Speaker

Chairperson(s)

Time

SIG Meeting on HE
Management of HE in outpatients

  1.   Burden Minimal/Covert HE – It matters in daily life?
  2.   Approach to manage a patient with covert HE
  3.   Lactulose, Rifaximin or both?
  4.   Primary/secondary prevention
  5.   Discussion -

60 min

10 min
15 min
10 min
10 min
15 min

 

RK Dhiman
Jasmohan Bajaj
Sunil Taneja
Barjesh Sharma

 

RK Dhiman
VA Saraswat

08.00-09.00

Day 2 Hall 3

 

Duration (min)

Speaker

Chairperson(s)

Time

SIG meeting on Ascites

  1.   What do we plan?
  2.   Management of refractory ascites
  3.   Beta Blockers in Cirrhotic Ascites: Recent advances
  4.   Recent advances in spontaneous bacterial peritonitis
  5.   Discussion

60 min

 

V. Singh
Rakhi Maiwall
Paolo Angeli
S K Sarin

 

V Singh
Rakhi Maiwall

08.00-09.00

Day 3 Hall 1

 

Duration (min)

Speaker

Chairperson(s)

Time

SIG meeting on ACLF

60 min

-------------
-------------

S.K Acharya
VA Saraswat

08.00-09.00

Day 3 Hall 2

 

Duration (min)

Speaker

Chairperson(s)

Time

SIG meeting on  DILI

  1.   What have we achieved thus far? The way forward!
  2.   Adaptation or DILI: That is the question
  3.   Newer concepts in DILI: 
      1.   DILI caused by biological, checkpoint inhibitors used to treat cancers, monoclonal antibody-induced DILI
      2.   HILI (herbal induced liver injury), SILI (statin-induced liver injury), CASH (chemotherapy associated steatohepatitis)
  4.   Discussion

60 min
10 min
15 min

10 min

10 min

15 min

 

Harshad Devarbhavi
Mallikarjun

Harshad Devarbhavi

Varghese Thomas

H Devarbhavi
RK Dhiman

08.00-09.00